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Background: Recent clinical studies show that tyrosine kinase inhibitors slow the rate of lung function decline and
decrease the number of acute exacerbations in patients with Idiopathic Pulmonary Fibrosis (IPF). However, in the
murine bleomycin model of fibrosis, not all tyrosine kinase signaling is detrimental. Exogenous ligands Fibroblast
Growth Factor (FGF) 7 and 10 improve murine lung repair and increase survival after injury via tyrosine kinase FGF
receptor 2b-signaling. Therefore, the level and location of FGF/FGFR expression as well as the exogenous effect of
the most highly expressed FGFR2b ligand, FGF1, was analyzed on human lung fibroblasts.
Methods: FGF ligand and receptor expression was evaluated in donor and IPF whole lung homogenates using
western blotting and qPCR. Immunohistochemistry for FGF1 and FGFR1/2/3/4 were performed on human lung
tissue. Lastly, the effects of FGF1, a potent, multi-FGFR ligand, were studied on primary cultures of IPF and non-IPF
donor fibroblasts. Western blots for pro-fibrotic markers, proliferation, FACS for apoptosis, transwell assays and
MetaMorph analyses on cell cultures were performed.
Results: Whole lung homogenate analyses revealed decreased FGFR b-isoform expression, and an increase in FGFR
c-isoform expression. Of the FGFR2b-ligands, FGF1 was the most significantly increased in IPF patients; downstream
targets of FGF-signaling, p-ERK1/2 and p-AKT were also increased. Immunohistochemistry revealed FGF1 co-localization
within basal cell sheets, myofibroblast foci, and Surfactant protein-C positive alveolar epithelial type-II cells as well as
co-localization with FGFR1, FGFR2, FGFR3, FGFR4 and myofibroblasts expressing the migratory marker Fascin. Both
alone and in the presence of heparin, FGF1 led to increased MAPK-signaling in primary lung fibroblasts. While smooth
muscle actin was unchanged, heparin + FGF1 decreased collagen production in IPF fibroblasts. In addition,
FGF1 + heparin increased apoptosis and cell migration. The FGFR inhibitor (PD173074) attenuated these effects.
Conclusions: Strong expression of FGF1/FGFRs in pathogenic regions of IPF suggest that aberrant FGF1-FGFR signaling
is increased in IPF patients and may contribute to the pathogenesis of lung fibrosis by supporting fibroblast migration
and increased MAPK-signaling.Introduction
Idiopathic pulmonary fibrosis (IPF) is a rare interstitial
lung disease of unknown origin, with prevalence rates
ranging from 2-4/10000 [1]. Diagnosis usually occurs in
the sixth and seventh decades of life and incidence appears
to be rising in older males [2]. Despite the recent approvals* Correspondence: Saverio.Bellusci@innere.med.uni-giessen.de
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inhibitor, Nintedanib [4] in both Europe and the
USA, IPF is still characterized by 5-year survival rates
that approximate 10-15 % [1].
Both Fgf7 and Fgf10 are mesenchymal-derived growth
factors that signal in a paracrine manner to bind with
high affinity to epithelial expressed Fgfr2 b-isoform [5].
Overexpression or administration of exogenous fibroblast
growth factors (Fgf)-7/10 [6, 7] diminishes the extent of
epithelial injury and apoptosis thereby attenuating
bleomycin-induced lung fibrosis in rodents. In addition,
attenuation of the mesenchymal expressed c-isoform ofss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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fibrosis [8]. Thus, in the bleomycin model of lung fibrosis,
enhanced Fgfr2b-isoform signaling may confer epithelial
repair and survival, while c-isoform Fgf-signaling may
support or maintain fibrosis. Fgf1, also known as heparin
binding growth factor, or acidic Fgf, is expressed by both
mesenchymal and epithelial cell types in the lung [9] and
binds with high affinity to all Fgfrs [10]. Thus, Fgf1 may
play multiple roles during lung repair as it signals to Fgfrs
expressed by both epithelial and mesenchymal cell types.
Fgf/Fgfr-binding is stabilized by heparin and transduced
by a phosphorylation cascade, mediated by fibroblast
growth factor receptor substrate (Frs2) [11] which activates
PI3k and Mapk-signaling pathways and/or activation of
phospholipase C gamma (Plc-γ) [12]. Signaling culminates
in survival, growth and/or differentiation of cells depending
on the context. Fgf-Fgfr induced Mapk-signaling is nega-
tively regulated by Spry2 [13–15] and Spry4 [16], both of
which are activated by Erk and inhibit the Mapk pathway
by binding to the Mapk kinase, Raf. Etv4, also known as
Pea3, is also a target of Fgf-signaling [17]. Increased Etv4
expression is associated with increased cell invasion [18]
and metastasis in lung cancer [19].
Until now, studies investigating the activity of heparin
+ FGF1 in the context of lung fibrosis have been carried
out exclusively on cell lines. Treatment of lung fibroblast
cell-line N12, with heparin + FGF1 had no impact on
proliferation but induced apoptosis and decreased smooth
muscle actin production [20]. Moreover, FGF1 in the
presence of heparin reversed TGF-beta1-mediated
epithelial to mesenchymal transition (EMT) of A549
and RLE-6TN epithelial cell lines [21]. Taken together,
these studies implicate FGF1 as an anti-fibrotic factor.
This is the first study to investigate the level and location
of FGF1 and FGFRs using IPF and donor (non-IPF) lung
tissues. This study revealed strong expression of FGF1
and FGFR receptors in pathogenic areas characteristic
of IPF including basal cell sheets and fibroblastic foci.
In addition, FGF1 and FGFRs co-localized with the
previously described cell invasion marker, Fascin [22].
Therefore, despite evidence from previous publications, this
study hypothesized that aberrant, increased FGF1-FGFR
signaling contributes to lung remodeling in IPF. Contrary
to studies performed previously on N12 fibroblast cell lines,
no significant changes in smooth muscle actin production
was detected in primary lung fibroblasts treated with
heparin + FGF1. However, a trend towards decreased
collagen 1a1 production was observed. In agreement
with these studies [20], primary lung fibroblasts isolated
from end-stage IPF patients and treated with FGF1 in the
presence of heparin showed no change in proliferation but
displayed increased apoptosis. Upon further analyses,
transwell migration assays as well as MetaMorph analyses
of cell motility indicated increased migration in fibroblastsexposed to FGF1 + heparin. These effects were attenuated
in the presence of an FGFR-signaling inhibitor; PD173074.
These results suggest that FGF1-FGFR-signaling in the
presence of heparin may contribute to lung remodeling by
enhancing invasive capabilities of fibroblasts. Moreover,
these results illustrate the potentially dual nature of FGF1-
signaling in the lung and may indicate a mechanism by
which endogenous FGF1-signaling plays both a protective
(epithelial cell survival and fibroblast apoptosis) and
pathological role (fibroblast invasion) in IPF.
Material and methods
Ethics statement
The study protocol for tissue donation was approved by
the Ethics Committee of the Justus-Liebig-University
School of Medicine (AZ 111/08). Informed consent was
obtained from each individual patient or next of kin.
Human tissue
Lung homogenates from IPF (n = 36) or donors (n = 15)
were obtained during transplantation at the Department
of Cardiothoracic Surgery, University of Vienna, Austria or
University Hospital Giessen-Marburg, Giessen, Germany
and processed as previously described [3].
Western blot
Loading buffer was added to protein samples from
cell extracts (5 % SDS in bromophenol blue and β-
mercaptoethanol) denatured for 5 min at 95 °C and
cooled on ice. At least 10 μg of sample was loaded
on a 10 % polyacrylamide gel and run at 25 mA for 2 h
then transferred to a polyvinylidene fluoride (PVDF)
membrane (Amersham) by semi-dry electro-blotting
(70 mA per gel; gel size: 7×9 cm) for 90 min. The mem-
brane was blocked with 5 % milk in TBS-blocking buffer
at RT for 1 h followed by 4 °C incubation with primary
antibody overnight. Membranes were washed in 1X TBST
buffer four times and incubated with HRP-labeled
secondary antibody at RT for 1 h followed by washing
with 1X TBS-T. Bands were detected by ECL (Enhanced
Chemi-luminescence, Amersham, Germany) treatment,
followed by exposure of the membrane. (Antibody infor-
mation is available in Additional file 1: Supplementary
Methods).
Quantitative PCR
RNA was reverse-transcribed (Qiagen QuantiTect Reverse
Transcription Kit (205313). cDNA was diluted to 20 ng/μL.
Primers were designed to span introns using Roche Applied
Sciences online Assay Design Tool. Sybr Green Master Mix
(Applied Biosciences 4309155) was used for qPCR with a
Roche LightCycler480 machine. Samples were run in tripli-
cates using PGBD as a reference. Primers are available in
Additional file 1: Supplementary methods.
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Human lungs were placed in 4 % (w/v) paraformaldehyde
for 12-24 h, and processed for paraffin embedding. 3 μm
sections were cut and mounted on slides (Super Frost Plus,
Langenbrinck). Paraffin-embedded tissue sections of donor
and IPF-lungs were deparaffinized in xylene and rehydrated
in graded alcohol. Antigens were retrieved by microwave
antigen retrieval (800 W); in 10 mmol/L freshly prepared
citrate buffer (pH 6.0) for 5 min. For immunostaining, the
streptavidin-biotin-alkaline phosphatase (AP) - or the
streptavidin-biotin- horseradish peroxidase (HRP) method
was used with the ZytoChem-Plus AP Kit (Fast Red),
Broad Spectrum (Zytomed Systems, Berlin, Germany)
according to the manufacturer’s protocol. Sections
were counterstained with hemalaun (Mayers hemalaun
solution, WALDECK Division CHROMA GmbH &
CO KG, Münster, Germany) and mounted in Glycergel
(DakoCytomation). Control sections were treated with 2 %
BSA in PBS alone or with rabbit or mouse primary antibody
isotype control (#_NB810-56910 and #_AM03096PU-N,
Acris Antibodies GmbH, Germany) to determine the speci-
ficity of the staining. Lung tissue sections were scanned with
a Mirax Desk slide-scanning device (Mirax Desk, Zeiss,
Germany), and examined histo-pathologically at 50×,
100×, 200×, 400×. IHC for mentioned antibodies was
performed in at least 8 IPF and 5 control-lung samples. A
complete list of antibodies and dilutions is provided in the
online supplement.
IPF and non-IPF fibroblast cell culture
5 cm lung cubic biopsies of human lung tissue were
washed in PBS and cut into small pieces in growing culture
medium: Dulbecco's Modified Eagle's Medium (DMEM)
with 10 % Fetal calf serum (FCS) 1 % glutamine, and 1 %
Penicillin-Streptomycin. Pieces were seeded initially in a
large 75 cm2 flask and grown out at 37 °C, 5 % CO2 for up
to one month with weekly media changes according to a
previously published protocol [23]. No enzymatic digestion
was performed. Non-attached cells were washed away, and
adherent fibroblasts remained. After the second passage,
fibroblasts were frozen in 10 % DMSO, 10 % FCS and
DMEM and stored in liquid nitrogen. Cells were
thawed, seeded and treated with human recombinant
FGF1 (R&D Systems #231-BC-025) with or without
heparin (Sigma #H3149) or FGFR inhibitor PD173074
(Tocris Bioscience #3044).
Annexin V FACS assay
The affymetrix APC annexin V and propidium iodide stain-
ing kit was used to perform an apoptosis assay according to
manufacturers instructions (eBioscience #88-8007-74) on
an Accuri C6 flow cytometer (BD Biosciences). Briefly, cells
were washed twice in cold PBS, then trypsinized at 37 °C
for 5 min. 2 wells of fibroblasts grown in 6-well plateswere gently collected, combined and pelleted. Pellets were
washed in PBS, followed by binding buffer, and incubated
first with kit antibody, then propidium iodide in the dark
for 10 min. At least 30,000 cells were counted per FACS
experiment. Gating was established based on plots of
propidium iodide alone and annexin V alone.
Transwell assay
Primary lung fibroblasts were starved for 24 h and
seeded (12,000 cells/well) in the upper chamber of the
transwell (6.5-mm transwell inserts with 8.0 μm pore size
polycarbonate membrane CLS3422-48EA, Sigma Aldrich)
containing serum free DMEM F-12 medium and the
lower chambers with various experimental conditions.
The system was incubated at 37 °C, 5 % CO2 to allow the
migration of cells through the membrane (8.0 μm). After
16 h, media was removed using a gentle suction and cells
were washed with 1X PBS, fixed with methanol and
stained with crystal violet. Next, the transwell was
swabbed to remove the non-migrated cells and the total
number of migrated cells was quantified using phase
contrast microscope.
MetaMorph analyses of cell motility
Fibroblasts from at least 3 biologically unique samples
were seeded at low density, in a 24-well-plate, starved
24 h, and underwent various treatments. The plate was set
on a motorized stage in a 5 % CO2 and 37 °C environment.
Random regions were marked, and Leica Live Imaging
Software snapped a photo of these regions every 5 min for
20 h. LIF files were exported and analyzed in Leica
MetaMorph software version 1.5.0. The average total
distance traveled of at least 6 random cells per group
were tracked and recorded.
Statistical analyses
A Student’s t-Test was performed on the log-transformed
value of the qPCR fold changes. For western blots, t-tests
were performed on the probit values. One-way ANOVAs
with Dunnet’s test (untreated groups served as controls)
were performed on Transwell and MetaMorph data.
Results
FGF1-FGFR1/2/3 as well as downstream targets PI3K- and
MAPK-signaling were increased in whole lung
homogenates of end-stage IPF patients
Western blots were performed for FGFR2b ligands
FGF1, FGF7, and FGF10. A significant increase in FGF1
was observed in IPF patients (Fig. 1a,b). FGF7 and
FGF10 protein levels were not significantly different
(Fig. 1a,c,d). In addition, FGFR1 (Fig. 1a,e), FGFR2
(Fig. 1a,f) and FGFR3 (Fig. 1a,g) were upregulated in IPF
lungs, while FGFR4 was unchanged. Next, downstream
pathways activated by growth factor signaling, including
Fig. 1 (See legend on next page.)
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Fig. 1 Western blot and qPCR analyses of IPF and donor whole lung homogenate lysates and RNA revealed increased FGF1-FGFR expression.
Western blots were performed on end-stage IPF (IPF) and non-IPF, donor lung homogenate lysates for FGF, MAPK and PI3/K signaling markers
(a). Densitometry plots of arbitrary units indicated a significant increase in FGF1 (b), no increase in FGF7 (c), FGF10 (d). Receptors FGFR1 (e), FGFR2
(f), FGFR3 (g) but not FGFR4 (h) were increased in IPF samples as well as p-ERK1 (i), p-ERK2 (i’) and p-AKT (j). ACTA2 and COL1A1 transcripts were
increased in IPF samples (k) as well as FGFR2b ligand transcripts: FGF1, FGF7, (l) and FGF10 (m). B-isoforms of FGFRs were decreased (n) while
FGFR2 c-isoform was significantly increased (o). Expression of FGFR3 was variable and FGFR4 (p) was not changed between IPF and donor
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(MAPK) and phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3K), [24] were analyzed. Both p-ERK1 and
p-ERK2 were increased in IPF samples (Fig. 1a, I-I’)
as well as, p-AKT (Fig. 1a,j). In addition, qPCR was
performed on FGF ligands and receptor transcripts.
IPF samples showed characteristic increases in Smooth
muscle actin (ACTA2) and Collagen 1a1 (COL1A1)
transcripts (Fig. 1k). A trend towards an increase in
FGF1 transcript in IPF lungs was observed (Fig. 1l).
FGF7 and FGF10 transcripts were also increased
(Fig. 1m). While the overall trends in the direction of the
changes of expression were similar, mRNA transcription
profiles did not always correlate exactly with the protein
expression profiles. Post-transcriptional regulation of
RNA by microRNAs and/or heterogeneous homogenates
may account for the discrepancies. As antibodies used
against FGFR receptors were not isoform specific, qPCR
was performed to determine which isoforms of FGFRs
were increased. Epithelial b-isoform expression of
FGFR1 and 2 were decreased in IPF homogenates
while FGFR3b transcript expression was variable (Fig. 1n).
The mesenchymally expressed c-isoform of FGFR2 and to
some extent FGFR3, were increased while the expression
of FGFR1c and FGFR4 were unchanged (Fig. 1o,p). These
data suggest that despite the increase in FGF7 and FGF10,
which have been shown to attenuate lung injury in mice,
the low level of FGFR2b receptor suggests that epithelial
FGFR2b-signaling may be reduced in IPF patients. In
contrast, the abundant expression of FGFR c-isoform, and
availability of FGF1 ligand suggested that FGF1-FGFRc
signaling may be increased in IPF patients.
Immunohistochemistry on serial sections revealed
co-localization of FGF1 with both epithelial and
mesenchymal derived cells in pathogenic regions of
IPF as well as co-localization with FGFR1, FGFR2, FGFR3,
FGFR4, and Fascin
Non-IPF alveolar epithelium revealed faint, expression of
FGF1 in pro-SP-C+ alveolar epithelial type II cells
(AECII, Fig. 2; a1-2). FGFR1 staining was absent, and
(Fig. 2, a3-4)FGFR2 indicated moderate expression in
normal proSP-C+ AECII cells (Fig. 2; a5-6) whereas
FGFR3 and FGFR4 were robustly expressed by this cell type
(Fig. 2; a7-8 and a9-10, respectively). The co-localization of
FGF1 and FGFR with spindle-shaped, α-SMA positive cellswas observed (Fig. 2; b1-6). Alveolar macrophages of nor-
mal donor lungs also stained positive for FGF1 as well as
for FGFR1-4 (Additional file 2: Figure S1).
FGF1 co-localized with α-SMA+ vascular smooth muscle
cells (VSMCs) of donor lungs (Fig. 2; b2,8 vs. B1,7). In
addition, FGFR1 (Fig. 2; b3,9 vs. B1,7) and FGFR2 stained
VSMCs (Fig. 2; b4,10 vs. b1,7) as well as FGFR3 and
FGFR4 (Fig. 2; b5,11 and b6,12, respectively).
In IPF lungs, FGF1 was present in SpC+, hyperplastic
AECII cells, overlying regions of fibrosis (Fig. 3; a1-2). No
or only weak FGFR1 staining was observed (Fig. 3; a3-4).
FGFR2 was strongly expressed by proSP-C+ alveolar
epithelium (Fig. 3; a5). as well as FGFR3 and FGFR4
(Fig. 3; a7 and a9, respectively). Alveolar macrophages also
stained strongly for FGF1 as well as for FGFR2 and 4.
FGFR1 and 3 staining of macrophages was faint
(Additional file 3: Figure S2).
One characteristic phenotype of IPF lung architecture
is the abnormal proliferation of basal cells (Keratin-5+)
which assemble into ‘sheets’, [25] (Fig. 3, b1,2). In addition,
α-SMA+, spindle-shaped myofibroblasts comprise usual
interstitial fibrotic foci (FF) particular to IPF (Fig. 3; b7,8).
The cytoskeleton actin-bundling protein Fascin [22, 26]
was also used to identify potentially migrating cells of the
FF (Fig. 3, b3,4). Basal cells were positive for Fascin (Fig. 3;
b1,2 vs. b3,4) as well as many α-SMA positive fibroblasts
(Fig. 3; b3,4 vs. b7,8). FGF1 was expressed by Keratin-5,
Fascin, and α-SMA positive cells (Fig. 3; b5,6 vs. b1,2; b3,4
and b7,8 respectively). A similar pattern was observed
for both FGFR1 (Fig. 3; B9,10) and FGFR2 (Fig. 3;
B11,12) though FGFR2 was more strongly expressed
overall than FGFR1 (See also Additional file 4: Figure S3).
α-SMA positive fibroblasts also express FGFR3 and
FGFR4 (Fig. 3, b13-16)
Keratin 5-staining was also used to identify bronchial
epithelium of IPF lungs (Fig. 4a; 1,2 and Fig. 4b; 1,2). In
addition, α-SMA+ was detected in highly condensed
regions of smooth muscle cells (swhich surrounding the
bronchioles) that are phenotypically distinct from the
long, spindle-shaped α-SMA+ myofibroblastic cells of usual
FF lesions which will be referred to in this manuscript as
regions of “dense” smooth muscle (Fig. 4; a3 and b5,6). In
the bronchial epithelium, FGFR1 lightly stained some
bronchial epithelial cells (Fig. 4a; 5,6). In contrast to
α-SMA+ myofibroblasts of usual FF regions, FGF1 was
mostly absent in regions of ‘condensed’ smooth muscle
Fig. 2 Expression and localization of FGF1 and FGF-receptors FGFR1, FGFR2, FGFR3 and FGFR4 in non-IPF, donor control lungs. Representative
immunohistochemistry for FGF1 (a1), FGFR1, FGFR2, FGFR3, and pro-surfactant protein C (proSP-C) in serial sections of normal control-lung tissue.
Alveolar epithelial type-II cells (AECII, indicated by arrows) of normal lungs do not express FGF1 (a1,2) and FGFR1 (a3,4), but indicate moderate
expression of FGFR2 (a5,6) and robust expression of FGFR3 (a7,8), and FGFR4 (a9,10). Representative immunohistochemistry for FGF1, FGFR1,
FGFR2, FGFR3, and alpha-smooth-muscle-actin (α-SMA) in serial sections of normal control-lung tissue. Vascular smooth muscle cells (upper and
middle panels) showed strong expression of FGF1 (b2,8) and FGF-receptors FGFR1 (b3,9), FGFR2 (b4,10), FGFR3 (b5,11), and FGFR4 (b6,12). Scale
bars: a1-10 (25 μm); b1-6 (250 μm), b7-12 (100 μm)
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expressed (Fig. 4a; 9,10), FGFR3 (Fig. 4b; 7,8) was nuclear,
and FGFR4 was strongly present in the bronchial
epithelium cytoplasm, and revealed also notable, but
moderate expression in the dense smooth muscle
(Fig. 4b; 9,10). Lastly, von Willebrand factor (vWF)
positive endothelial cells did not show co-localization
with FGF1, FGFR1 or FGFR2 staining (Additional file 5:
Figure S4, A,B).
Given the strong expression of FGF1 and FGFR1/2/3/4
in regions of usual interstitial FF, as well as their co-
localization with the migratory marker Fascin, and the
myofibroblast marker α-SMA, the effect of exogenous
FGF1 on IPF lung fibroblasts was addressed.
FGF1 + heparin treatment of IPF and donor fibroblasts
resulted in activation of the MAPK pathway and reduced
COL1a1 production
IPF and non-IPF, donor fibroblasts (2 technical replicates
of 6 independent biological samples) were harvested and
cultured as previously described [27]. Cells were starved for
24 h and then treated once daily for two days with culture
medium alone (line 1) heparin (25 ng/mL, line 2), recom-
binant human FGF1 (25 ng/mL, line 3), heparin + FGF1together (line 4), the FGFR inhibitor, PD173074
(0.1 μM resuspended in DMSO, line 5), DMSO
(0.1 μM) only (line 6), or heparin + FGF1 + PD173074
inhibitor simultaneously (line 7).
Heparin + FGF1 treatment of IPF fibroblasts resulted
in a trend towards decreased collagen production by IPF
fibroblasts while no effect was observed on non-IPF
fibroblasts (Fig. 5 a–c, compare line 4 to line 1). In the
presence of the inhibitor, the reduction of collagen was
partially attenuated. Contrary to previous reports using
fibroblast cell lines, heparin + FGF1 did not significantly
decrease α-SMA production (Fig. 5a,d).
The trend towards decreased collagen production in
IPF fibroblasts treated with heparin + FGF1 may be in
part regulated via activation of p-ERK1/2 signaling. The
p-ERK1/2 signal was significantly increased in both
FGF1 alone and FGF1 + heparin treated IPF fibroblasts
(Fig. 5e,f,g). The p-ERK2 signal was significantly attenuated
in fibroblasts treated with inhibitor alone versus untreated
control, suggesting a high level of cell autonomous
FGF-FGFR-signaling by IPF fibroblasts. In addition, the
inhibitor efficiently blocked p-ERK activation by exogen-
ous heparin + FGF1 in both donor and IPF fibroblasts
(Fig. 5e,f,g). DMSO had no effect. A trend towards an
Fig. 3 Expression and localization of FGF1 and FGF-receptors FGFR1, FGFR2, FGFR3 and FGFR4 in hyperplastic, overlying alveolar epithelium,
fibroblastic foci and basal cell sheets in idiopathic pulmonary fibrosis (IPF) lungs. a. Representative immunohistochemistry for FGF1, FGFR1,
FGFR2, FGFR3, and prosurfactant protein C (pro-SP-C) in serial sections of IPF lung tissue. Alveolar epithelial type-II cells (AECII, indicated by arrows)
of IPF lungs express FGF1 (a1,2), FGFR2 (a4,5), FGFR3 (a6,7), and FGFR4 (a8,9), but not FGFR1 (a3,4). b. Representative immunohistochemistry for
Cytokeratin-5 (KRT5) (b1,2), Fascin (b3,4), FGF1 (b5,6) α-SMA (b7,8), FGFR1 (b9,10), and FGFR2 (b11,12) in serial sections of IPF lung tissue. In IPF,
immunostaining for FGF1, FGFR1 and FGFR2 was observed in myofibroblasts of fibroblast foci [FF] (indicated by arrowheads and α-SMA-staining)
as well as in overlying hyperplastic bronchiolar basal cells (indicated by asterisks and KRT5-staining), and colocalized with expression of the
migratory marker Fascin (2). Representative immunohistochemistry for α-SMA (b13), FGFR3 (b14) and FGFR4 (b15) and FGF1 (b16) in serial
sections of IPF lung tissue. In general, α-SMA-positive myofibroblasts of FF (indicated by arrowheads) express FGF1, FGFR3 and FGFR4. Of note,
FGFR3 expression appeared predominantly nuclear in AECII as well as myofibroblastic cells. Scale bars: a1-9 (100 μm); b1,3,5,7,9,11 (250 μm),
b2,4,6,8,10,12 (100 μm), b13-16 (100 μm)
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in heparin + FGF1 treated fibroblasts (Fig. 5e,h). However,
this marker was not regulated following the addition of
the FGFR inhibitor.
In summary, the FGFR inhibitor PD173074 efficiently
mitigated both endogenous and exogenous FGFR mediated
p-ERK signaling. Furthermore, FGF1 + heparin did not
significantly attenuate α-SMA production nor did it
significantly regulate Fascin. However, COL1a1 produc-
tion trended towards a decrease in this group. Due to thesubstantial activation of p-ERK signaling following
heparin + FGF1 treatment, whether proliferation and
apoptosis were influenced was tested next.
Heparin + FGF1 treatment induced apoptosis but did not
affect proliferation
Flow cytometry was performed on treated donor and
IPF fibroblasts for Annexin V and propidium iodide. In
accordance with previous reports [20, 28], the number
of apoptotic cells (Annexin V positive and propidium
Fig. 4 Overexpression of FGF1 and FGF-receptors FGFR1, FGFR2, FGFR3 and FGFR4 in hyperplastic bronchioles in remodelled areas of dense
fibrosis in idiopathic pulmonary fibrosis (IPF) lungs. a Immunohistochemistry for KRT5 (a1,2), α-SMA (a3,4), FGFR1 (a5,6), FGF1 (a7,8) and FGFR2
(a9,10) in serial sections of IPF lung tissue. Moderate immunostaining for FGFR1, but very strong staining for FGF1and FGFR2 is observed in
basal and luminal bronchial epithelial cells of abnormal, hyperplastic bronchioles (indicated by KRT5-staining) surrounded by dense fibrotic
regions. b Representative immunohistochemistry for KRT5 (b1,2), FGF1 (b3,4), α-SMA (b5,6), FGFR3 (b7,8) and FGFR4 (b9,10) in serial sections
of IPF lung tissue. In IPF, bronchial epithelial cells of abnormal bronchioles in areas of bronchiolization and dense fibrosis indicate robust
expression of FGF1, FGFR3 and FGFR4. Scale bars: a1,3,5,7,9 (250 μm); a2,4,6,8,10 (50 μm), b1,3,5,7,9 (250 μm), b2,4,6,8,10 (50 μm)
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treated with heparin + FGF1 compared to starved,
non-treated controls: 20 % vs. 40 % in donor fibro-
blasts (Fig. 6a,b) and 18 % vs. 50 % in IPF fibroblasts
(Fig. 6a,b’). Apoptosis due to heparin + FGF1 treat-
ment was partially mitigated in the presence of the
FGFR inhibitor (Fig. 6a,b,b’). The gating strategy is
shown in Additional file 6: Figure S5. As in previous
studies performed on fibroblast cell lines [20], no sig-
nificant change in the expression of proliferating cell
nuclear antigen (PCNA) was detected in donor or IPF
fibroblasts (Fig. 6c,d,d’).
Heparin + FGF1 treatment stimulated migration of donor
and IPF fibroblasts
To further investigate potential functional effects of
exogenous FGF1 + heparin on primary lung donor and
IPF fibroblasts, both transwell migration experiments
and MetaMorph analyses of cell cultures were performed.
The FGFR inhibitor alone (0.1 μM) did not inhibit
migration through the transwell (Fig. 7a,b). The addition
of heparin + FGF1 stimulated significant migration andwhen added in the presence of the FGFR inhibitor, this
effect was mitigated (Fig. 7a,b,c). A control experi-
ment showed that the FGFR inhibitor also attenuated
migration stimulated by 5 % FCS (Additional file 7:
Figure S6 A,B,C). While the addition of FGF1 alone
or heparin alone did not stimulate migration in donor
fibroblasts, these conditions stimulated migration in IPF
fibroblasts, but to a lesser extent than heparin + FGF1
together (Additional file 7: Figure S6 D,E,F).
MetaMorph analyses of low-density fibroblasts cultures
revealed that heparin + FGF1 stimulated IPF fibroblasts to
travel longer distances than non-stimulated fibroblasts
(Fig. 7d). In this system, addition of the inhibitor alone re-
duced distance travelled in both donor and IPF fibroblasts
and mitigated the effect of exogenous heparin + FGF1 in
IPF fibroblasts when added simultaneously. Unlike the
transwell assay, FGF1 alone had no effect on IPF fibroblasts,
while heparin alone reduced distance travelled.
In summary, heparin + FGF1 stimulated migration of
both IPF and donor fibroblasts and this effect could
be attenuated by the simultaneous addition of FGFR
inhibitor.
Fig. 5 Impact of exogenous FGF1 + heparin on the regulation of pro-fibrotic proteins. Western blots were performed on lysates harvested from
IPF and non-IPF (donor) fibroblasts (2 technical replicates of 6 independent biological samples). Cells were starved for 24 h (lane 1) and then
treated once daily for two days with heparin (25 ng/mL) (lane 2) recombinant human FGF1 (25 ng/mL) (lane 3), FGF1 + heparin together
(lane 4), the FGFR inhibitor, PD173074 (0.1 μM resuspended in DMSO) (lane 5), DMSO (0.1 μM) only (lane 6), or FGF1 + heparin + PD173074
(lane 7) simultaneously. Collagen 1a1 (COL1a1, bands present at both 170 and 140kDA) was blotted against b-tubulin (TUBB1) (a) and smooth
muscle actin (ACTA2/α-SMA) was blotted against GAPDH (b). Densitometry plots of arbitrary units indicated that in donor fibroblasts, COL1a1 was
not significantly regulated (b,c) and neither was ACTA2 (α-SMA) (a,d). Untreated lysates of IPF fibroblasts displayed more collagen than in donor
controls (a). COL1a1, especially the 170kDA band, was strongly reduced in FGF1 + heparin groups (b,c) while ACTA2 was not regulated (a,d). Next
p-ERK1/2 was blotted over total ERK (e,f,g), and Fascin (e,h), a cell invasion/migration marker. In donor fibroblasts, p-ERK1 signal was significantly
increased in the FGF1 alone group and reduced in the presence of the inhibitor (e,f). The p-ERK2 signal was increased in donor fibroblasts where
exogenous FGF1 or heparin or both were added and p-ERK2 was attenuated in the presence of the inhibitor (e,g). In IPF fibroblasts, p-ERK1 was
significantly activated when exposed to FGF1 alone or FGF1 + heparin and attenuated when the inhibitor was present (e,f) and p-ERK2 was
similarly regulated (e,g). A trend towards an increase in the cell migration marker Fascin was observed in FGF1 + heparin treated donor and
IPF fibroblasts (e, h)
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FGF1/FGFR expression is increased in IPF
In the rodent bleomycin-model, enhanced Fgfr2b-signaling
on alveolar epithelial cells via the exogenous application or
induction of FGF10 or FGF7, conferred increased survival
and reduced lung fibrosis [7, 29]. On the other hand,
attenuation of mesenchymal Fgfr2c-isoform signaling,
led to decreased bleomycin-induced fibrosis [8]. These
experiments suggest that in the context of lung fibrosis, apotential benefit is conferred via enhanced epithelial
FGFR2b-signaling and decreased mesenchymal FGFR2c-
signaling. This study is the first to describe the expression
of FGFR2b-ligands (FGF1/7/10) and FGFR1/2/3/4 recep-
tors in IPF. This study found that b-isoforms of FGFR1/2
receptors were decreased and c-isoform of FGFR1/2/3
were increased in IPF lungs suggesting an increase in
FGF1/FGFR c-isoform signaling in IPF patients. However,
the real contribution of endogenous FGFR-signaling to
Fig. 6 (See legend on next page.)
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Fig. 6 Impact of exogenous FGF1 on cell death and cell proliferation on fibroblasts from IPF and donor lungs. FACS plots (a) represent flow
cytometry performed on treated donor and IPF fibroblasts for Annexin V (detected with the FL4A channel) and propidium iodide (detected
with the FL2A channel). Cells were starved for 24 h and then treated once daily for two days with heparin (25 ng/mL) recombinant human FGF1
(25 ng/mL), FGF1 + heparin together, FGF1 + heparin + PD173074 (0.1 μM resuspended in DMSO), or as positive control 1uM Staurosporine
(resuspended in DMSO) 18 h before harvest for experiment. Graphic representation of the percentage of apoptotic cells (Annexin V positive and
propidium iodide negative) for donor fibroblasts (20 % vs. 40 %) (b) and IPF fibroblasts (18 % vs. 50 %) (b’); n = 4 biological samples/treatment
group. The gating strategy is shown in Additional file 6: Figure S5. Western blot for proliferating cell nuclear antigen (PCNA) against GAPDH
(c). Densitometry plots of arbitrary units indicated no significant regulation of PCNA in various treatment groups (d,d’)
Fig. 7 Impact of exogenous FGF1 on cell migration of IPF vs. Donor fibroblasts. Primary lung fibroblasts were starved for 24 h and seeded (12,000
cells/well) in the upper chamber of the transwell (6.5-mm transwell inserts with 8.0-μm pore size). Untreated (group 1) PD173074 (0.1 μM), (group
2), recombinant human FGF1 + heparin (25 ng/mL each) (group 3) or FGF1 + heparin + PD173074 (group 4) was added to the lower wells. Cells
migrated for 16 h, were fixed and stained with crystal violet (a). The fold change of the number of migrated donor fibroblasts (b) and IPF
fibroblasts (c). In both cases, PD173074 alone had no effect, FGF1 + heparin stimulated migration and and migration was attenuated in the FGF1
+ heparin + PD173074 groups. Additional control experiments are available in Additional file 7: Figure S6. Graphs represent MetaMorph analyses
of fibroblasts cultures for 18 h; blue = donor, red = IPF; total distance traveled in 18 h (d). FGF1 + heparin stimulated IPF fibroblasts to travel longer
distances while no effect was observed in non-IPF, donor fibroblasts. Experiments were repeated in triplicate. Scale bars: (100 μm)
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suggested that FGF-signaling contributes to increased
angiogenesis in IPF via FGF2/FGFR2-signaling, the role of
angiogenesis in IPF remains controversial and should be
further studied [30, 31].
FGF1 emerged as the most highly expressed FGFR2b-
binding ligand in IPF lung homogenates. FGF1 is
expressed by both mesenchymal and epithelial cell types
in the lung [9] and binds not only to FGFR2b, but with
high affinity to all FGFRs [10]. The binding is also
stabilized in the presence of heparin [32]. Whether
FGF1 plays a pathogenic role in IPF, has not been
thoroughly investigated. The hypoxic environment in IPF
lungs may induce FGF1 expression, as FGF1 expression
was shown to be strongly induced in rats exposed to
hypoxia [33]. In addition, mast cells and basophils, whose
numbers are increased in IPF, may provide a source of
heparin [34] which in turn may augment FGF1 + heparin
signaling on cells exposed to alveolar spaces. Furthermore,
chronic obstructive pulmonary disease (COPD) is associ-
ated with enhanced bronchial expression of FGF1 and
FGFR1 as well as FGF2 [35].
In this study, FGF1 and FGFR1/2/3 were increased at
the protein level in whole lung homogenates taken
from end-stage IPF patients compared to non-IPF lung
homogenates. IHC analyses revealed robust expression
of FGF1 in regions of irregular lung architecture par-
ticular to IPF, including: basal cell sheets or basal
cells of hyperplastic bronchioles (Fig. 4a and b) and
SMA+/Fascin + myofibroblasts of fibroblastic foci, and
areas of thickened bronchial epithelium. Robust expression
by macrophages was also observed. FGFR1 was faintly
expressed in basal cells and myofibroblasts whereas FGFR2
was expressed very robustly in these cells, as well as also in
SPC+ expressing alveolar epithelial type-II cells (AECII)
and macrophages. FGFR3 was also highly expressed by
AECII, bronchial cells, myofibroblasts and macrophages.
Similarly, FGFR4 was expressed by nearly all epithelial cells
and by myofibroblasts of fibroblastic foci. Taken together it
is likely that FGF1-FGFR signaling is increased in regions
of lung remodeling specific to IPF. Furthermore, given the
reduction of p-ERK in fibroblasts treated with FGFR
inhibitor, it is likely that FGF1/FGFR contributes to
the overall increase in p-ERK1/2 and p-AKT signaling
detected in whole lung homogenates which has also been
previously reported [36]. Unchecked MAPK-signaling, in
part sustained by increased FGF1/FGFR-signaling in IPF
fibroblasts, may be a key mechanism by which activated
fibroblasts persist in the fibrotic foci. Tyrosine kinase
inhibitors such as Nintedanib, also known as BIBF1120 or
Vargatef, block pathways that feed in to the MAPK
pathway such as FGF, PDGFR and VEGF, which leads to
reduced MAPK-signaling [37] and may be a mechanism
by which this drug hinders disease progression.FGF1 + heparin treatment of IPF fibroblasts resulted in
increased apoptosis and decreased collagen production
but had no effect on smooth muscle actin
Former in vitro studies suggest that FGF1 may have an
anti-fibrotic effect on lung fibroblasts. For example,
heparin + FGF1 was found to decrease smooth muscle
actin production and had a pro-apoptotic effect on a
normal lung fibroblast cell line [20]. In addition, after
induction of epithelial to mesenchymal transition (EMT)
via Transforming growth factor β (TGF-β) stimulation of a
human epithelial cell line (A549), FGF1 + heparin returned
epithelial and mesenchymal markers to levels of non-
stimulated cells [21]. Thus, heparin + FGF1 was capable of
reversing TGF-β-mediated EMT via MAPK-dependent
signaling. Similar results were obtained using the mouse
lung epithelial cell line, MLE-12 (data not shown). In
accordance with previous work, a decrease in COL1a1
production was observed by primary lung IPF fibroblasts
exposed to heparin + FGF1. This result was not elicited in
donor lung fibroblasts, as the level of collagen detected in
donor fibroblasts was already very low. However, in con-
trast to previous in vitro studies performed on fibroblast
cell lines, alpha smooth muscle actin (α-SMA) was not
significantly regulated. The reduction in COL1a1 may be
linked to the increase in p-ERK signaling which was
elicited more strongly in IPF lung fibroblasts than
donor lung fibroblasts. This stronger response by IPF
lung fibroblasts may be due to distinct heparin sulfate
proteoglycan formation on the IPF fibroblast cell surface,
which may result in IPF fibroblasts being more amenable
to heparin + FGF1 stimulation. Likewise, p-ERK signaling
was inhibited by the addition of an FGFR inhibitor
both alone and in the presence of exogenous heparin +
FGF1. This strong increase in p-ERK signaling may
also contribute to increased apoptosis of fibroblasts
via MAPK-mediated activation of p38 [38, 39]. As
previously observed in fibroblast cell lines [20, 40],
both donor and IPF fibroblasts, heparin + FGF1 treatment
resulted in increased apoptosis but no change in prolifera-
tion was observed.
FGF1 + heparin treatment of IPF and non-IPF lung
fibroblasts increased cell migration
FGF1 and FGFR co-localization with the motility and in-
vasion marker Fascin was observed in usual interstitial fi-
broblastic foci. In addition, a preliminary scratch assay
experiment revealed that FGF1 + heparin treated IPF fi-
broblasts closed a scratched area of confluent fibroblasts
faster than untreated cells (data not shown). Although
Fascin expression was not observed to be significantly reg-
ulated by heparin + FGF1, the failure of heparin + FGF1 to
reduce SMA expression, the preliminary scratch assay
data, the absence of FGF1 from condensed regions of
smooth muscle cells, as well as previous studies indicating
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further investigation.
The addition of heparin + FGF1 stimulated significant
migration of both IPF and non-IPF fibroblasts through a
transwell filter compared to starved, untreated cells.
When heparin + FGF1 were added in the presence of the
FGFR inhibitor, this effect was mitigated. Interestingly,
while the addition of FGF1 alone or heparin alone did
not stimulate migration in donor fibroblasts, these con-
ditions stimulated migration in IPF fibroblasts, but to a
lesser extent than heparin + FGF1 together. These results
suggest that IPF fibroblasts may be primed to receive
chemotactic signals. Faster migration by IPF fibroblasts
may also be due to enhanced p-ERK1/2 signaling as stron-
ger activation of p-ERK1/2 by FGF1 alone and heparin +
FGF1 was also observed in IPF fibroblasts compared to
donor, non-IPF fibroblasts used in this study.
In addition, MetaMorph analyses of low-density cul-
tures of fibroblasts revealed that heparin + FGF1 stimu-
lated IPF fibroblasts to travel longer distances while no
effect was observed in non-IPF, donor fibroblasts. Unlike
the transwell experiments, addition of the inhibitor
alone reduced overall distance travelled in both donor
and IPF fibroblasts compared to untreated cells. How-
ever, as in the transwell experiments, the FGFR inhibitor
efficiently attenuated the effect of exogenous heparin +
FGF1 in IPF fibroblasts when added simultaneously.
Lastly, unlike the transwell assay, FGF1 alone had no ef-
fect on IPF fibroblasts, while heparin alone reduced dis-
tance travelled of IPF fibroblasts. The discrepancies
between the transwell and live imaging experiments may
be due the lack of a gradient formation in the 24-well
plates used for live imaging. In summary, MetaMorph
analyses of live imaging experiments support the conclu-
sion that the migration of IPF fibroblasts was enhanced
following exposure to heparin + FGF1.
Increased FGF1-FGFR signaling may contribute to lung
remodeling in IPF
In summary, this study described strong expression of
FGF1 and FGFR1/2/3/4 receptors in pathogenic areas of
IPF lungs and identified FGF1-FGFRs as potential
contributors to increased MAPK-activity in IPF. Though
IPF lung fibroblasts responded to heparin + FGF1 treat-
ment by attenuating COL1a1 expression and increased
apoptosis, increased p-ERK1/2 signaling along with
enhanced cell migration was also observed reflecting
a potentially dual nature of FGF1/FGFR in the context of
lung fibrosis. Though tyrosine kinase inhibitors have
recently been approved for the treatment of IPF, given the
multi-faceted nature of FGF1-FGFR signaling, further
studies should be designed to identify targets of growth
factor signaling that mediate specific cellular functions
such as fibroblast apoptosis and migration.Additional files
Additional file 1: Supplementary Methods.
Additional file 2: Figure S1. Co-localization of FGF1, FGFR1/2/3/4 with
macrophages (CD68+) in donor lung serial sections. Representative
immunohistochemistry on serial sections of non-IPF (donor) lung tissue
for FGFs and macrophages (CD68+). FGF1 (A1,6), FGFR2 (A3,8), FGFR3,
(A4,9) and FGFR4 (A5,10), were detected in macrophages, but FGFR1
(A2,7) was not. All scale bars: 50 μm.
Additional file 3: Figure S2. Co-localization of FGF1, FGFR1/2/3/4 with
macrophages (CD68+) in IPF lung serial sections. Representative
immunohistochemistry on serial sections of IPF lung tissue for FGFs and
macrophages (CD68+). FGF1 (A1,2), FGFR2 (A4,5), FGFR3, (A6,7) and
FGFR4 (A8,9), were detected in macrophages, but FGFR1 (A2,7) was not.
All scale bars: 100 μm.
Additional file 4: Figure S3. Co-localization on serial sections of FGF1,
FGFR1/2 in usual fibroblastic foci (α-SMA) IPF lung lesion and basal cell
sheet (KRT5) on serial sections. Representative immunohistochemistry on
additional serial sections of IPF lung tissue for FGFs basal cell sheets
(KRT5) and spindle-shaped myofibroblasts (α-SMA) of fibroblastic foci (FF).
Representative of basal cell sheets KRT5 (A1,6,11), FGF1 (A2,7,12), α-SMA
(A3,8,11), FGFR1 (A4,9,14) and FGFR2 (A5,10,15). FGFR2 and FGF1 were
strongly expressed in fibroblasts of FFs and to a lesser extent FGFR1.
Abnormal basal cell sheet covering fibroblastic foci (B1), (α-SMA) of FF
(B2), FGF1 is present in myofibroblasts and in basal cell sheets (B3),
and so is FGFR2 (B4). Scale bars: A1-5 (500 μm); A6-10 (250 μm),
A11-15; B1-4 (100 μm).
Additional file 5: Figure S4. Co-localization on serial sections of FGF1,
FGFR1/2 in areas of dense smooth muscle (α-SMA+) and vessels stained
with von Willibrand Factor (vWF) in IPF lungs. Representative
immunohistochemistry on serial sections of IPF lung tissue for FGFs
relative t dense smooth muscle (α-SMA) and vessels (vWF).
Representative of hyperplastic basal cells (KRT5+) (A1,7,13), dense
smooth muscle α-SMA (A2,8,14), FGFR1 is absent in endothelium
and lightly stains dense smooth muscle (A3,9,15). An additional
series of sections showing that FGF1, FGFR1 and FGFR2 are mostly
absent from endothelium (B1-5). Scale bars: A1-6 (500 μm);
A7-12 (100 μm), A13-18; B1-5 (50 μm).
Additional file 6: Figure S5. Gating strategy for Annexin V (AV)/
Propidium Iodide (PI) FACS. Gating was performed based on single
stained PI only stained cells (A) and Annexin V only stained cells (B).
Additional file 7: Figure S6. Impact of exogenous FGF1 on cell
migration of IPF vs. donor fibroblasts. Primary lung fibroblasts were
starved for 24 h and seeded (12,000 cells/well) in the upper chamber of
the transwell (6.5-mm transwell inserts with 8.0-μm pore size). Cells
migrated for 16 h, and were then fixed and stained with crystal violet.
(n = 3/treatment group) (C,F). 5%FCS stimulated migration of donor
fibroblasts (A, C1-4) and IPF fibroblasts (B, C5-8) and these effects were
attenuated by the simultaneous addition of 0.1uM and 1.0uM of
PD173074. The addition of heparin or FGF1 alone did not stimulate
migration in donor fibroblasts, however the addition of both factors
significantly stimulated migration (D, F1-4). In contrast, both heparin and
FGF1 alone stimulated migration of IPF fibroblasts, but not as significantly
as FGF1 + heparin together (E, F5-8). Scale bars: (100 μm).
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